Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vibegron (Primary)
Indications Abdominal pain
Focus Proof of concept; Therapeutic Use
Sponsors Urovant Sciences

Most Recent Events

01 Dec 2022 Results assessing the efficacy and safety of the beta3 -adrenergic agonist vibegron in treating irritable bowel syndrome related pain published in the Neurogastroenterology and Motility
25 Nov 2020 Status changed from active, no longer recruiting to completed.
24 Nov 2020 According to a Urovant Sciences Media Release, the company will continue to analyze the full data set of this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com